“…The following demographic and clinical data were prospectively collected: age, sex, hypertension, diabetes mellitus, hyperlipidemia, current or former smoking habit, previous stroke or transient ischaemic attack, atrial fibrillation, heart failure, prior use of antiplatelets, prior use of oral anticoagulants, prior use of statins, National Institutes of Health Stroke Scale (NIHSS) score at baseline and at 24 h. The following radiological and procedural data were prospectively collected: baseline ASPECT score, occlusion site (intra‐cranial ICA occlusion, M1‐segment MCA occlusion and M2‐segment MCA occlusion), good collaterals according to the Careggi Collateral Score (CCS) from 2 to 4 [7], intravenous thrombolysis (IVT) <4.5 h from symptom onset, type of anesthesia (general or conscious sedation), type of procedure (stent retriever or aspiration), onset‐to‐groin puncture time, procedure time, types of hemorrhagic transformation (HT) according to the European Cooperative Acute Stroke Study (ECASS) II classification (hemorrhagic infarction type 1 [HI‐1] defined as small petechiae along the margins of the infarct; hemorrhagic infarction type 2 [HI‐2] defined as more confluent petechiae within the infarcted area but without space‐occupying effect; parenchymal hemorrhage type 1 [PH‐1] defined as a clot not exceeding 30% of the infarcted area with some mild space‐occupying effect; parenchymal hemorrhage type 2 [PH‐2] defined as dense blood clot exceeding 30% of the infarct volume with significant space‐occupying effect [8] at 24 h), types of cerebral edema (CED) according to the Safe Implementation of Thrombolysis in Stroke Monitoring Study (SITS‐MOST) classification (CED‐1 defined as focal brain swelling up to a third of the hemisphere; CED‐2 defined as greater than a third of the hemisphere; CED‐3 defined as midline shift) [9] at 24 h and mRS score at 3 months.…”